Question 1

Am I eligible for this trial based on my treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer clinical trial (NCT05158062). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer clinical trial (NCT05158062). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer clinical trial (NCT05158062). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer clinical trial (NCT05158062). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer clinical trial (NCT05158062). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or procedures I would need to undergo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer clinical trial (NCT05158062). Contact the study team or your healthcare provider for specific answers.

What this study is about